CRXM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 Feb 2024 @ 14:22):

Stats
Today's Volume	300.00
Average Volume	0.00
Market Cap	65.00
EPS	$0 ( 2021-04-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2021-03-31	Jemapete Christopher J	Buy	0
2021-03-17	Jemapete Christopher J	Buy	200 000	Common Stock
2021-03-16	Jemapete Christopher J	Buy	300 000	Common Stock
2021-02-26	Jemapete Christopher J	Sell	0	Common Stock
2015-03-23	Hutchison Murray H	Buy	50 000	Warrant to purchase Common Stock

INSIDER POWER
0.00
Last 8 transactions
Buy: 750 000 \| Sell: 0

Volume Correlation

Long: -0.43 (neutral)

Short: -1.00 (very strong negative)

Signal:(52.013) Neutral

Gene Biotherapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gene Biotherapeutics, Correlation - Currency/Commodity

0.00
( neutral )

Gene Biotherapeutics, Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0360

FY	2019
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$0.0500

Financial Reports:

No articles found.

Gene Biotherapeutics,

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.